Avita Medical (NASDAQ:RCEL) Stock Rating Upgraded by Wall Street Zen

Avita Medical (NASDAQ:RCEL – Get Free Report) was upgraded by Wall Street Zen from a “hold” rating to a “buy” rating in a note issued to investors on Saturday, Wall Street Zen reports.

Several other research analysts also recently commented on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Avita Medical in a report on Monday, September 21st. BTIG Research boosted their target price on shares of Avita Medical from $15.00 to $21.00 and gave the stock a “buy” rating in a research report on Friday, November 6th. TD Cowen upped their price target on shares of Avita Medical from $20.00 to $22.00 and gave the company a “buy” rating in a report on Thursday. Finally, Lake Street Capital raised their price target on Avita Medical from $12.00 to $20.00 and gave the company a “buy” rating in a research report on Friday, November 6th. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Avita Medical has a consensus rating of “Moderate Buy” and a consensus price target of $16.60.

Read Our Latest Stock Analysis on Avita Medical

Avita Medical Price Performance

NASDAQ RCEL opened at $15.63 on Friday. Avita Medical has a fifty-two week low of $3.22 and a fifty-two week high of $18.43. The stock’s 50-day moving average is $13.40 and its two-hundred day moving average is $7.16. The firm has a market cap of $491.09 million, a P/E ratio of -13.25 and a beta of 2.03.

Avita Medical (NASDAQ:RCEL – Get Free Report) last announced its quarterly earnings results on Thursday, November 5th. The company reported ($0.20) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.04. The company had revenue of $26.11 million during the quarter, compared to analyst estimates of $22.35 million. On average, equities analysts expect that Avita Medical will post -0.94 EPS for the current year.

Hedge Funds Weigh In On Avita Medical

Several large investors have recently added to or reduced their stakes in the company. BlackRock Inc. bought a new stake in shares of Avita Medical in the 2nd quarter worth about $2,333,000. NewEdge Advisors LLC lifted its holdings in Avita Medical by 71.4% during the 2nd quarter. NewEdge Advisors LLC now owns 148,931 shares of the company’s stock valued at $615,000 after purchasing an additional 62,046 shares during the last quarter. Bank of America Corp DE bought a new position in Avita Medical during the 2nd quarter valued at about $213,000. Marshall Wace LLP lifted its holdings in Avita Medical by 107.1% during the 3rd quarter. Marshall Wace LLP now owns 700,745 shares of the company’s stock valued at $8,220,000 after purchasing an additional 362,358 shares during the last quarter. Finally, Russell Investments Group Ltd. lifted its holdings in Avita Medical by 47.7% during the 3rd quarter. Russell Investments Group Ltd. now owns 41,449 shares of the company’s stock valued at $486,000 after purchasing an additional 13,395 shares during the last quarter. Institutional investors and hedge funds own 27.66% of the company’s stock.

Avita Medical Company Profile

(Get Free Report)

AVITA Medical is a regenerative medicine company focused on treatments for skin restoration. Its flagship technology, the RECELL System, enables clinicians to use a small sample of a patient’s healthy skin to prepare a suspension of skin cells for application to wounds. The company’s RECELL products are used in the treatment of burns and certain other skin injuries, including full-thickness skin defects. The approach is intended to support wound coverage while reducing the amount of donor skin needed compared with conventional skin-grafting procedures.

Further Reading

Analyst Recommendations for Avita Medical (NASDAQ:RCEL)

Receive News & Ratings for Avita Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avita Medical and related companies with MarketBeat.com's FREE daily email newsletter.